The FDA accepts GSK's BLA seeking approval of Blenrep combinations for treating relapsed/refractory multiple myeloma. A decision is due on July 23, 2025.
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License ...
US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, November 26, 2024, 09:00 Hrs [IST] GSK plc an ...
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab ...
The US Food and Drug Administration (FDA) is expected to make a Prescription Drug User Fee Act (PDUFA) decision by mid-2025.
GlaxoSmithKline (GB:GSK) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now ...
Pharma titan GSK has announced that US regulators have accepted for review Blenrep combinations for the treatment of relapsed ...
GSK PLC said on Monday that the US Food & Drug Administration accepted a biologics license application for its Blenrep combinations for the treatment of relapsed and refractory multiple myeloma, both ...
GSK plc (GSK, GSK.L) announced that the US Food and Drug Administration has accepted for review a Biologics License Application (BLA) ...
There is a history of competition law being used to drive HIV medicine prices lower in South Africa. Now, two cases involving ...
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
A ground breaking study mapping the immune microenvironment in Multiple Myeloma identifies critical immune changes and ...